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Introduction
In Finland, incidence of CDI increased during 2002-
2006, shown by the population-based analysis of hospital
discharge diagnoses, a trend similar to that in the US. In
2008, toxin-positive C. difficile became a notifiable dis-
ease. During the first 3 years of surveillance, the annual
incidence decreased from 111 to 90/100,000 population,
but rose up to 100 in 2011. The epidemic situation and
trends differed regionally. Both PPI and FQ use have
been associated with increased risk of CDI.
Objectives
To study whether the use of antibiotics, FQs and PPIs
were associated with regional differences in CDI rates.
Methods
Data on CDI incidence during 2008-2011 in 21 hospital
districts (HD) was obtained from the National Infectious
Disease Registry and consumption of antibiotics and
PPIs from the Finnish Medical Agency. The availability
of molecular methods in diagnostics was obtained by a
laboratory survey and data on FQ resistant ribotypes
from the national reference laboratory. Negative bino-
mial regression model was performed to assess the
impact of different antibiotics, PPIs, the presence of
ribotype 027 CD and the use of molecular diagnostic
methods in the respective HD on CDI incidence. Vari-
able selection in the model was done by using Akaike
information criteria (AIC).
Results
The level of FQ use was stable during 2008-2011
(although it had doubled during 1990-2000). The use of
PPI increased 50% during 2008-2011. FQ use was strongly
associated with the CDI incidence, and there was a trend
between PPI use and the CDI incidence in different HDs.
The presence of molecular methods (including PCR) or
the knowledge of ribotype 027 being detected in the HD
was not associated with the CDI incidence. According to
AIC, in the final multivariable model, we only included
FQ use. The incidence rate ratio for FQs was 2.45 (95%CI,
1.58-3.79; p<0.001).
Conclusion
FQ use was an important risk factor for CDI, as shown
previously. However, the use has stabilized during the last
few years. In the national guidelines, FQs are included in
the choices to treat urinary tract infections but not respira-
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